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Abstract
The recent rise of multidrug-resistant Gram-negative bacteria represents a serious threat to
public health and makes the search for novel effective alternatives to antibiotics a compel-
ling need. Bacteriophage (Phage) lysins are enzymes that hydrolyze the cell wall of bacteria
and represent a promising alternative to tackle this ever-increasing problem. Despite their
use is believed to be restricted to Gram-positive bacteria, recent findings have shown that
they can also be used against Gram-negative bacteria. By using a phage genome-based
screening approach, we identified and characterized a novel lysin, PlyE146, encoded by an
Escherichia coli prophage and with a predicted molecular mass of ca. 17 kDa. PlyE146 is
composed of a C-terminal cationic peptide and a N-terminal N-acetylmuramidase domain.
Histidine-tagged PlyE146 was overexpressed from a plasmid in Lactococcus lactis NZ9000
and purified by NI-NTA chromatography. PlyE146 exhibited in vitro optimal bactericidal
activity against E. coli K12 (3.6 log10 CFU/mL decrease) after 2 h of incubation at 37˚C at a
concentration of 400 μg/mL in the absence of NaCl and at pH 6.0. Under these conditions,
PlyE146 displayed antimicrobial activity towards several other E. coli, Pseudomonas aerugi-
nosa (3 to 3.8-log10 CFU/mL decrease) and Acinetobacter baumannii (4.9 to >5-log10 CFU/
mL decrease) strains. Therefore, PlyE146 represents a promising therapeutic agent against
E. coli, P. aeruginosa and A. baumannii infections. However, further studies are required to
improve the efficacy of PlyE146 under physiological conditions.
Introduction
The massive use of antibiotics has led to a rise of bacteria that are multidrug-resistant (MDR)
[1]. This phenomenon is particularly alarming in Gram-negative bacteria, including Escheri-
chia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii, which
are responsible for a broad spectrum of infections that could become untreatable [2,3]. The
rise of these MDR bacteria and the shortage of novel antibiotics warrants the search and the
development of new alternative antibacterial agents [1].
Bacteriophage lysins, namely phage-encoded enzymes that hydrolyze the cell wall peptido-
glycan of phage-infected bacteria for progeny release [4–6], represent a very promising novel
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alternative class of antimicrobial agents. In fact lysins, which generally have a broader spec-
trum activity than the producing phage, can ideally be exploited to eliminate specific bacterial
infections [4]. Other advantages offered by lysins are the rapidity of action, high efficiency and
the low chance to develop bacterial resistance since they target peptidoglycan components that
are essential for bacterial viability [7–9]. A possible drawback of lysin therapy could be the gen-
eration of neutralizing antibodies, as they are exogenous proteins. However, several studies
have shown that antibodies specific for lysins do not block their activity in vitro, and anaphy-
laxis was not observed in mice after repeated administration, implying that they can be utilized
more than once [10].
The use of lysins as potential therapeutic agents has been widely investigated against Gram-
positive bacteria, where when externally applied can induce rapid bacterial lysis due to the
direct accessibility to the peptidoglycan [4,11–13]. By contrast, Gram-negative bacteria possess
an outer membrane which protects the peptidoglycan from hydrolysis by phage lysins when
applied from outside [14]. Consistent to this notion, only a few lysins with intrinsic antimicro-
bial activity against Gram-negative bacteria have been reported so far [15–19]. As an example,
using a phage genome-based analysis Lai et al. have identified two lysins (A1S-1600 and A1S-
2016) which were active against several Acinetobacter spp. [20]. Using the same approach,
Lood et al. have more recently identified a lysin, namely PlyF307, which efficiently killed A.
baumannii in vitro and in vivo [19]. Of remark, PlyF307 is composed of an N-terminal N-acet-
ylmuramidase (lysozyme) domain [19] and a highly positively charged C-terminal domain,
suggesting that penetration through the outer membrane and subsequent hydrolysis of the
peptidoglycan substrate from the lysins may be mediated by cationic peptides. This concept
was supported by the observation that just the cationic peptides retained substantial antimicro-
bial activity towards A. baumannii [21]. Consistent to this notion, recent studies have shown
that lysins can be engineered to become active against Gram-negative bacteria by fusing the
N- or C- terminus with cationic peptides [22–24]. However, reports of lysins active against
Gram-negative bacteria remain limited and mostly focus on A. baumannii and P. aeruginosa.
In an attempt to identify novel lysins naturally active against E. coli, the C-terminal cationic
peptide of PlyF307, alias P307, was used as a query to search for translated proteins sequences
with similar properties in the E. coli genomes deposited in the NCBI database. In this study, a
novel E. coli phage lysin, namely PlyE146, was identified and its antimicrobial activity against a
panel of Gram-negative and Gram-positive bacteria was evaluated. PlyE146 was shown to effi-
ciently kill in vitro several strains of E. coli, P. aeruginosa and A. baumannii.
Materials and methods
Bacterial strains and growth conditions
The bacterial strains used in this study are described in Table 1. They include a broad range of
reference strains as well as clinical isolates. E. coli, K. pneumoniae, P. aeruginosa, A. baumannii
and Salmonella enterica strains were grown at 37˚C in LB medium (Difco Laboratories,
Detroit, MI). Staphylococcus aureus was cultured at 37˚C in tryptic soy broth (TSB; Difco) and
Streptococcus mitis was grown at 37˚C in brain-heart infusion (BHI; Difco). L. lactis NZ9000,
used as a host for protein overexpression, was grown at 30˚C in M17 medium (Difco) supple-
mented with 0.5% [wt/vol] glucose (GM17).
Bioinformatics analysis
The peptide P307 (amino acids 108 to 138 of PlyF307) [19] was blasted against all the E. coli
proteomes available in the protein database of NCBI. The top hit was one lysin (GenBank
accession N˚ EKK47578) of 146 amino acids encoded from an E. coli 8.0569 prophage. The
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protein, that we named PlyE146, was found to possess a C-terminal domain with 68%
sequence identity to P307.
Cloning of lysin plyE146
plyE146 was synthetized by Eurofins Genomics (Ebersberg, Germany) and cloned in the pET-
28a expression vector (Novagen, Madison, WI) using NcoI and XhoI restriction sites. The
resulting plasmid expressed PlyE146 fused to a 6His tag at its C-terminus was electroporated
into electrocompetent E. coli BL21 (DE3). Isopropyl β-D-1-thiogalactopyranoside (IPTG)-
mediated induction of plyE146 expression led to growth arrest of logarithmic E. coli BL21 cells.
Therefore, the plyE146-6His gene was sub-cloned into the Lactococcus lactis nisin-controlled
gene expression system (NICE) pNZ8148, resulting in the construct pNZ8148-plyE146-6His.
Briefly, plyE146-6His was amplified from the pET28a-plyE146 construct by polymerase chain
reaction (PCR) using primers sml289 (5’-GAAATAATTTTGTTTAACTTTAAGAAGGAG-3’)
(forward), which is complementary to a sequence upstream the NcoI recognition site and
sml293 (5’-ATATATCTAGAGACCCGTTTAGAGGCCCCAAGG-3’)(reverse), containing the
XbaI recognition site (underlined). The resulting DNA fragment of 613 bp was digested with
NcoI and XbaI restriction enzymes (Promega, Madison, Wisconsin, USA) and ligated into
pNZ8148, also digested with the same enzymes. The ligation mixture was electroporated into
electrocompetent L. lactis NZ9000 cells. Transformants were selected on GM17 plates contain-
ing 10 μg/ml chloramphenicol. The presence of the insert into pNZ8148 was verified by com-
mercial DNA sequencing (GATC Biotech, Konstanz, Germany).
Table 1. Bacterial strains used in this study.
Strain Source and Relevant characteristic(s)a
Gram-negative
E. coli DH5α Reference strain
E. coli K12 Reference strain
E. coli 8542 Strain from patient with sepsis, ESBL-producer
E. coli S115 Strain from patient with urinary tract infection, Imipenem-R,Colistin-R
E. coli 17 Strain from patient with sepsis, Amoxicillin-S, Ciprofloxacin-S
E. coli 23 Strain from patient with sepsis, Amoxicillin-R, Ciprofloxacin-R
E. coli 35 Strain from patient with peritonitis, Amoxicillin-S, Ciprofloxacin-S
E. coli 52 Strain from patient with skin infection, Amoxicillin-S, Ciprofloxacin-S
K. pneumoniae 8354 Strain from patient with sepsis, ESBL-producer
S. enterica Strain from patient with bacteremia
P. aeruginosa ATCC 27853 Reference strain
P. aeruginosa UR1156 Strain from patient with bacteremia, Imipenem-R
P. aeruginosa 2062 Strain from patient with sepsis, Imipenem-R
A. baumannii H12555 Strain from burn patient, Ciprofloxacin-R
A. baumannii 33 Strain from patient with sepsis, Imipenem-R
A. baumannii FER Strain from patient with sepsis, AmpC β-lactamase-producer, Imipenem-R
Gram-positive
S. aureus ATCC 25913 Reference strain
S. mitis 859 Nasopharynx isolate, Penicillin-R
L. lactis NZ9000 pNZ8148 Expression strain, Chloramphenicol-R
aESBL: extended spectrum β-lactamase; R: resistant
https://doi.org/10.1371/journal.pone.0192507.t001
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Protein overexpression and purification
PlyE146 was overexpressed from pNZ8148-plyE146-6His in L. lactis NZ9000 cells. Cells were
grown aerobically in GM17 containing 10 μg/ml of chloramphenicol at 30˚C with gently shak-
ing (40 r.p.m.) until the mid-exponential phase (OD600 = 0.4). Protein expression was induced
for 18 h at 30o C by addition of 100 ng/ml of nisin.
Lactococcal cells containing overexpressed PlyE146 were harvested by centrifugation and
then resuspended in 15 ml of binding buffer (100 mM NaH2PO4, 500 mM NaCl, 5 mM imid-
azole, pH 7.4). After incubation for 1 h at room temperature with 4 mg/ml of lysozyme, cells
were disrupted by four passages through a French press at 30 MPa and incubated for 15 min
on ice with 10 μg/ml RNAse and 10μg/ml DNase. The cell debris were removed by centrifuga-
tion (30 min at 8000 rpm). The cleared lysate (ca. 30 ml) was mixed with 2 mL of Ni-NTA
resin (Qiagen, Hilden, Germany) and incubated overnight at 4˚C in an end-to-end rotor. The
slurry was then loaded onto a disposable polypropylene column and washed with 20 ml of
binding buffer and 10 ml of washing buffer (100 mM NaH2PO4, 500 mM NaCl, 30 mM imid-
azole, pH 7.4). PlyE146-6His was eluted with 5 ml of elution buffer (100 mM NaH2PO4, 500
mM NaCl, 300 mM imidazole, pH 7.4). The eluate was dialyzed overnight against sodium
phosphate monobasic dehydrate (NaPi) buffer (20 mM NaH2PO4•2H2O, pH 6.0). Purity of
PlyE146 was determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE).
Western blot analysis
Western blotting using an anti-histidine antibody was performed to confirm presence of the
expected PlyE146 protein in the eluate. The protein samples were resolved by SDS-PAGE and
then transferred to an Immobilon-P membrane (Millipore, Billerica, Massachusetts, USA) for
1.5 h at 60 V. After blocking with 5% (w/v) skimmed milk in PBS (milk/PBS), the membrane
was incubated with 1:100 dilution of rabbit serum containing anti-6His antibody (final con-
centration, 1μg/mL) for 1 h. After four washes in milk/PBS, the membrane was incubated in
milk/PBS with 0.5 μg/mL (final concentration) of a goat anti rabbit horseradish peroxidase
(HRP) secondary antibody for 1 h. After four washes with PBS the blots were incubated with
the western bright ECL solutions (Advansta, Menlo Park, CA) at a 1:1 ratio. The ECL signal
was captured with a Fusion FX apparatus (Witec AG, Luzern, Switzerland).
Antibacterial activity of PlyE146
The antibacterial activity of PlyE146 was initially tested against ca. 107 CFU/mL logarithmic-
and stationary-phase E. coli K12, which was used as reference strain. Bacterial cells were first
washed in NaPi buffer (pH 6.0) and then incubated in the same buffer with different concen-
trations of PlyE146 (ranging from 3.1 to 500 μg/mL). Buffer without lysin was used as a nega-
tive control. After 2 h of incubation at 37˚C with shaking (200 rpm) [19], samples were serially
diluted and plated on agar plates. Viable cells were enumerated after overnight incubation of
the plates at 37˚C. Bactericidal concentration was defined as a3 log10 decrease in cell counts
as compared to that in the absence of lysin. Experiments were performed in triplicate and data
expressed as mean ± standard deviation (SD).
To study the effect of pH and NaCl on the activity of PlyE146, logarithmic-phase E. coli K12
cells were incubated for 2 h at 37˚C with 400 μg/mL of PlyE146 (the minimal bactericidal con-
centration,) in NaPi buffer with different pH values (6.0 to 9.0) or NaCl concentrations (0 to
500 mM).
Time-kill curve assays with exponentially growing (OD600 = 0.4) E. coli K12 cells (ca. 107
colony forming units [CFUs]/mL) were performed under optimal conditions for PlyE146
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bactericidal activity, namely in NaPi buffer (pH 6.0) with no NaCl and a protein concentration
of 400 μg/mL After 0.5, 1, 2, 3 and 4 h of incubation at 37˚C with shaking (200 rpm), aliquots
were serially diluted and plated on agar plates. Viable cells were enumerated after overnight
incubation of the plates at 37˚C. Bactericidal concentration was defined as described above.
Experiments were performed in triplicate and data expressed as mean ± SD.
To test the effect of the outer membrane-permeabilizer ethylenediaminetetraacetic acid
(EDTA) on the activity of PlyE146, logarithmic- and stationary-phase E. coli K12 cells were
pretreated with 5 mM EDTA before being incubated with PlyE146 (400 μg/mL) in NaPi buffer
(pH 6.0) for 2 h at 37˚C.
The spectrum of antimicrobial activity of PlyE146 (400 μg/mL) was tested against a panel of
16 Gram-negative bacteria (8 E. coli, 3 P. aeruginosa, 3 A. baumannii, 1 K. pneumoniae and 1 S.
enterica) and 2 Gram-positive bacteria (1 S. aureus and 1 S. mitis). The assay was performed
using bacteria in the exponential phase of growth using the aforementioned conditions. Viable
cells were enumerated after 2 h of incubation. Experiments were performed in triplicate and
data expressed as mean ± SD.
The effect of the serum on the activity of PlyE146 was analyzed with logarithmic growing
E. coli K12, P. aeruginosa UR1156 and A. baumannii FER strains, three isolates that were effi-
ciently killed in vitro (see Results) under optimal conditions for PlyE156 bactericidal activity
(pH 6.0 and no salt). The experiments were conducted in triplicate in decomplemented
human serum (by heating at 56˚C for 30 min) and the results expressed as mean ± SD.
Transmission electron microscopy (TEM)
TEM was used to visualize the effects of PlyE146 on bacterial cells. TEM was performed on
mid-logarithmic phase (OD600 = 0.4) A. baumannii strain FER (used as a model organism)
using 400 μg/mL of PlyE146 or buffer as control. After 1 h incubation, cells were fixed with
glutaraldehyde at a final concentration of 25% and washed with PBS. Cells were then treated
with metaperiodate (1% final concentration, 15 min incubation) and osmium tetroxide plus
hexacyanoferate (1% and 1.5%, respectively. 1 h incubation). Cells were then centrifuged and
the pellets were spun down in microcentrifuge tubes containing melted agar. After solidifica-
tion of the agar, pellets were embedded in epon for ultra-thin sections (50 nm) preparation as
described [25]. Micrographs were taken with a transmission electron microscope FEI CM100
(FEI, Eindhoven, the Netherlands) at an acceleration voltage of 80 kV with a TVIPS TemCam-
F416 digital camera (TVIPS GmbH, Gauting, Germany).
Results
Identification of plyE146 and purification of PlyE146
In an endeavor to identify natural lysins active against E. coli, the peptide P307 (amino acids
108 to 138 of the previously described lysin PlyF307 active against A. baumannii) [19] was
used as a query against all the E. coli proteomes (translated protein sequences) available in
NCBI. A putative bacteriophage lysin of 146 amino acids (GenBank accession N˚ EKK47578)
encoded in the E. coli 8.0569 genome was the best hit. The putative lysin, that we named
PlyE146, exhibits 57.7% sequence identity with PlyF307. The putative protein presents a N-ter-
minal muraminidase domain and a C-terminal domain with a predicted hairpin-like di-alpha
helical structure linked by a flexible unstructured region (Fig 1A; structure prediction gener-
ated using I-TASSER server [26,27]), which resembles that one of P307 (21). Moreover, the C-
terminal peptide comprising amino acids 108–138, hereafter P146, exhibits 68% identity with
P307 (Fig 1B). Notably, 6 of the 9 positively charged amino acid residues of P307 are also
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present in P146, despite only 3 are identical. In aggregate, the C-terminal domains of PlyE307
and PlyE146 exhibit a high degree of conservation.
To assess the antimicrobial activity of purified PlyE146, the encoding gene was cloned in
the expression vector pET28a. E. coli cells were transformed with the resulting plasmid,
expressing PlyE146 fused to a six-histidine tag (6His) at its C-terminus (pET28-PlyE146-
6His). However, the expression of PlyE146-6His in exponentially growing E. coli cells led to
growth arrest, suggesting a lethal effect exerted by PlyE146-6His. Thus, plyE146-6His was sub-
cloned in an inducible expression system (pNZ8148) suitable for L. lactis. Overexpression in L.
lactis NZ9000 and purification by Ni-NTA agarose affinity chromatography yielded a soluble
protein (PlyE146-6His, from now on referred to as PlyE146) that migrated on SDS-PAGE at
the expected molecular mass of 17 kDa.
Western blot
To further verify the nature of the 17 kDa protein band, western blot was performed using pri-
mary rabbit anti-histidine antibodies and secondary goat anti-rabbit antibodies coupled to
HRP. As expected, a chemiluminescent band with a molecular size of approximately 17 kDa
was detected in the elution fraction, confirming its PlyE146-6His nature. Additional bands
with higher molecular weights, possibly corresponding to protein oligomers, were also present
in the eluate.
Fig 1. Structural prediction of the PlyE146 C-terminal domain and sequence alignment with P307. The C-terminal domain of PlyE146
(P146) assumes a hairpin-like di-alpha helical structure linked by a flexible unstructured region (A) and shares 68% identity with PF307 (B).
In blue are conserved amino acids, in yellow positively-charged amino acids and in green conserved, positively-charged amino acids.
https://doi.org/10.1371/journal.pone.0192507.g001
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PlyE146 antimicrobial activity
The bactericidal activity of PlyE146 against exponentially growing E. coli K12 cells was found
to be concentration-dependent. In fact, while low PlyE146 levels ( 25 μg/mL) did not affect
the viability of E. coli K12 after 2 h of incubation at 37˚C, concentrations between 25 and
200 μg/mL reduced titers of E. coli K12 by ca. 2 log10 CFU/mL. The lowest concentration of
PlyE146 with bactericidal activity (3.64 log10 kill) was 400 μg/mL (Fig 2). Similarly to other
lysins [13,19,23], the antimicrobial activity of PlyE146 was significantly lower against station-
ary-phase cells (<1 log10 kill).
The effects of pH and NaCl on the in vitro antibacterial activity of PlyE146 were also investi-
gated. The highest activity of PlyE146 was observed at pH 6.0 (reduction of 4 log10 CFU/mL of
the inoculum in buffer) (Fig 3). At higher pH, PlyE146 caused as little as1 log10 reduction of
cell viability (Fig 3). Moreover, NaCl exerted an inhibitory effect on PlyE146 activity. Indeed,
while the activity of PlyE146 was essentially preserved in the presence of 50 mM NaCl, it signif-
icantly decreased in the presence of NaCl concentrations100 mM (1.1 to 1.6 log10 CFU/mL
reduction). Based on these results, we elected to continue the in vitro experiments by testing
the bactericidal activity of PlyE146 after 2 h exposure against exponentially growing cells at pH
6.0 and at a concentration of 400 μg/mL.
To get a further insight into the mechanism of action of PlyE146, the antimicrobial activity
was monitored over time under the aforementioned conditions in a time-kill experiment. As
depicted in Fig 4A, the killing activity of PlyE146 started only after 60 min incubation (2.5
log10 CFU/mL decrease of viable E. coli) and became bactericidal (3.6 log10 CFU/mL decrease)
Fig 2. Bactericidal activity of PlyE146 on logarithmic growing E. coli K12 bacteria. E. coli K12 cells (106 to 107 CFU/mL) were exposed to
increasing concentrations of PlyE146 in NaPi buffer (pH 6.0) at 37˚C for 2 h, serially diluted and plated for colony counts. Results represent the
mean ± standard deviation of triplicate experiments.
https://doi.org/10.1371/journal.pone.0192507.g002
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at 2 h. No further reduction was observed at 4 h. Based on these findings, we tested whether
pre-treatment of E. coli K12 cells with the outer membrane permeabilizer EDTA could
enhance PlyE146 activity, as observed with other lysins [23]. Unexpectedly, addition of 5 mM
of EDTA did not have any effect on the activity of PlyE146 against E. coli (both logarithmic
and stationary phase cells) (Fig 4B), suggesting that PlyE146 can effectively penetrate the outer
membrane without prior destabilization and therewith reach the peptidoglycan substrate.
Spectrum of antibacterial activity of PlyE146
The spectrum of activity of PlyE146 was tested against a panel of 16 Gram-negative bacteria
and 2 Gram-positive bacteria. As shown in Fig 5, the antimicrobial activity of PlyE146 was
strain specific. PlyE146 efficiently killed 3 out of 8 E. coli (E.coli K12, E. coli DH5α and E.coli
ESBL 8542;>3.5 log10 CFU/mL decrease) but was less active against 5 other strains (ca. 1 log10
CFU/mL decrease). A similar pattern of activity was observed against P. aeruginosa; while the
activity towards strains ATCC 27853 and UR1156 was bactericidal (3.1 to and 3.9 log10 CFU/
mL decrease, respectively), strain 2062 was not susceptible to the lysin. A strong activity of
PlyE146 was observed against the three tested A. baumannii strains with4.9 log10 CFU/mL
decrease. No activity was observed against the tested K. pneumoniae, S. enterica, S. aureus and
S. mitis strains (Fig 5).
Antibacterial activity of PlyE146 in serum
The activity of PlyE146 was tested in decomplemented human serum against E. coli K12, P.
aeruginosa UR1156 and A. baumannii FER strains, three isolates that were efficiently killed in
vitro (see Fig 5). Interestingly, in the presence of serum, no activity of PlyE146 was recorded
against any of the tested bacteria.
TEM
The effect of the PlyE146 on A. baumannii structure was visualized by TEM on 50 nm sections.
As shown in Fig 6, exposure to 400 μg/mL of PlyE146 led to drastic changes in intracellular
density and to the disintegration of the cell wall and the cell membrane.
Discussion
Gram-negative bacteria are becoming increasingly resistant to antibiotics and this poses a
problem for the treatment of the associated infections. Due to the shortage of novel antibiotics,
innovative strategies must be developed. Lysins are phage-related enzymes that hydrolyze the
bacterial peptidoglycan and therefore represent an attractive option to tackle this issue. How-
ever, due to the presence of the outer membrane that hinders the access of the lysins to the
peptidoglycan of Gram-negative bacteria, lysins have been for long time considered useful
only against Gram-positive bacteria. Notwithstanding, recent works have shown that lysins
(natural or engineered) do possess antibacterial activity against P. aeruginosa and A. bauman-
nii [8,17,19,20], raising the prospect of a possible use for treating Gram-negative bacterial
infections too.
A common feature of lysins active against Gram-negative bacteria is the presence of a
highly cationic peptide at the C- or N-terminus that can potentially destabilize the outer
Fig 3. Effect of pH and NaCl on the antibacterial activity of PlyE146. To study the effect of pH (A) and NaCl (B) on E. coli K12, logarithmic
growing cells were exposed to PlyE146 (400 μg/mL) in NaPi buffer at different pH and NaCl concentrations for 2 h at 37˚C, serially diluted and
plated for colony counts. Results represent the mean ± standard deviation of triplicate experiments.
https://doi.org/10.1371/journal.pone.0192507.g003
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Fig 4. Time-kill curve and effect of EDTA on the antibacterial activity of PlyE146. For the time-kill experiments (A), logarithmic-phase growing
E. coli K12 cells were exposed to PlyE146 (400 μg/mL) in NaPi buffer (pH, 6.0) for 4 h at 37˚C. For EDTA experiments (B), logarithmic- and
stationary-phase growing E. coli K12 cells were exposed to PlyE146 (400 μg/mL) in the absence or the presence of EDTA (5 mM) in NaPi buffer (pH,
6.0) for 2 h at 37˚C. Results represent the mean ± standard deviation of triplicate experiments.
https://doi.org/10.1371/journal.pone.0192507.g004
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membrane of Gram-negative bacteria and give access to the peptidoglycan. This notion has
been supported by the work of Lood and others [19], which showed that the highly positively
charged C-domain of a phage lysin active against A. baumannii was sufficient to kill the bacte-
ria. Inspired by these observations, we searched similar lysins with antimicrobial activity to-
wards E. coli and identified PlyE146, a putative lysin with a predicted highly positively charged
C-terminal domain and an N-acetylmuramidase (lysozyme) N-terminal domain. PlyE146
exhibited a significant lethal activity against several E. coli and P. aeruginosa strains with a> 3
log10 CFU/mL decrease after 2 h of exposure. However, the antimicrobial activity against E.
coli and P. aeruginosa varied from strain to strain. To our knowledge, this is the first report of
an endolysin with significant intrinsic antibacterial activity towards E. coli. The only endoly-
sins with a reported killing activity against E. coli are the fusion E. coli phage Lysep3 lysins,
which exhibited a maximal activity comparatively lower than that of PlyE146 (slightly above of
1 log10 kill after 10 h exposure) (23). The killing activity of PlyE146 was much greater against
A. baumannii and resulted in ca. 5 log10 CFU/mL decrease for three clinical isolates tested. By
contrast, no activity was detected against K. pneumoniae and S. enterica isolates. This species
and strain-specificity, together with the apparent greater sensitivity of A. baumannii, might be
ascribed to different features at the level of the outer membrane structure, like a different com-
position in the lipopolysaccharides, which may prevent or facilitate the access to exogenous
lysins [23]. Consistent to what observed for other endolysins with intrinsic activity towards
Fig 5. Antibacterial activity of PlyE146 against different Gram-negative and Gram-positive bacteria. The assays were conduct with bacteria in logarithmic
growing phase, incubated with 400 μg/mL of PlyE146 in NaPi buffer (pH 6.0) at 37˚C for 2 h. The dashed line indicates the limit of detection.
https://doi.org/10.1371/journal.pone.0192507.g005
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Gram-negative bacteria [19], PlyE146 exerted its optimal activity at pH 6.0, suggesting a cen-
tral role played by the cationic peptide in providing access to the peptidoglycan substrate.
Indeed, at low pH the cationic peptide becomes more protonated and may thereby destabilize
more efficiently the outer membrane of Gram-negative bacteria through the interaction with
the negatively charged phosphates of the outer membrane by interfering with the stabilizing
divalent cations. Consistent to this notion, pretreatment of cells with the membrane-permeabi-
lizer EDTA [8] did not improve the activity of PlyE146. Of note, the presence of a 6-His tag in
the proximity of P146 might have had an effect on the putative translocating activity mediated
by P146, a possibility that is for further studies to determine.
In contrast to the fast kinetics generally observed with Gram-positive lysins [6] or the artifi-
cial lysin Art-175, where cell explosions could be observed within 5 min of exposure, the effects
of PlyE146 on E. coli K12 cells could be observed only after 30 min exposure and reached a
similar killing efficacy after 2 h treatment. This finding, which is in agreement with the results
obtained with for PlyF307, further supports the scheme of a two-step mechanism with an ini-
tial slow penetration of the outer membrane followed by the hydrolysis of the peptidoglycan
[19], as evidenced by the TEM analysis of A. baumannii cells after 2 h exposure to PlyE146.
Remarkably, even in the presence of a clear dispersion of the cell wall, Acinetobacter cells do
not appear to explode, as it generally occurs with Gram-positive lysins [13] or Art-175 [9],
where cells burst after the bulging of the cytoplasmic membrane through punctured holes in
the cell wall. Although the exact mode of killing is for further studies to be determined, the
slower activity of PlyE146 is likely behind this killing effect.
As expected, the activity of PlyE146 against E. coli cells in logarithmic phase was much
greater as compared to cells in stationary phase. Indeed, lysins have been reported to be gener-
ally less active against stationary-phase cells than against logarithmically growing cells [13].
Fig 6. TEM. Representative TEM images of 50 nm sections of untreated control (left panel) and PlyE146-treated (right panel) A. baumannii (strain FER). TEM
images show an evident disruption of the cell wall after exposure to PlyE146 (400 μg/mL) for 1 h.
https://doi.org/10.1371/journal.pone.0192507.g006
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This effect can be ascribed to the thinner peptidoglycan layer at the level of the septum in
growing cells, which makes it an easier pray for the lysin [13].
As previously shown for other lysins [21,23], PlyE146 became inactive against E. coli, P. aer-
uginosa and A. baumannii in serum. Absence of activity in serum as well as under physiologi-
cally relevant conditions, like in the presence of salts and at physiological pH 7.4, at the
moment precludes a potential use of PlyE146 as a therapeutic agent. A study is undergoing in
the laboratory to investigate whether modifications thereof can revert this loss of function.
In conclusion, we characterized a new E. coli prophage lysin able to efficiently kill different
Gram-negative bacteria in vitro. This study further demonstrates that bacteriophage lysins rep-
resent a promising alternative to antibiotics in the fight against MDR Gram-negative bacterial
pathogens.
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